Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: October 28, 2018
Event: Redemption of senior notes by Abbott Laboratories and its subsidiary, St. Jude Medical, LLC.
Key Financial Metrics and Debt Activity
The filing details the redemption of $3,996,600,000 in aggregate principal amount of senior notes. The transaction involved the following specific instruments and redemption prices:
- 4.125% Notes due 2020: $596,614,000 redeemed at 101.814% of principal.
- 2.000% Notes due 2020: $750,000,000 redeemed at 100.000% of principal.
- 3.400% Notes due 2023: $450,000,000 partially redeemed at 100.940% of principal. Remaining outstanding: $1,050,000,000.
- 3.750% Notes due 2026: $1,300,000,000 partially redeemed at 103.033% of principal. Remaining outstanding: $1,700,000,000.
- Abbott 3.25% Senior Notes due 2023: $818,429,000 redeemed at 100.297% of principal.
- STJ 3.25% Senior Notes due 2023: $81,557,000 redeemed at 100.297% of principal.
All redemptions included accrued and unpaid interest to, but excluding, the Redemption Date. The filing does not provide specific revenue, profit, cash flow, or margin figures for the period.
Material Changes
The primary material change is the reduction of the company's outstanding debt load by approximately $4.0 billion in principal. This action terminates the definitive agreements governing the fully redeemed notes and reduces the aggregate principal amount of the partially redeemed 3.400% and 3.750% notes.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure of the debt redemption mechanics. The transaction was executed in accordance with the terms of the respective indentures.
Investor Verification Checklist
- Verify the total cash outflow required for the redemption, including the premium amounts (e.g., 101.814% for 4.125% Notes) and accrued interest.
- Confirm the remaining outstanding principal balances for the 3.400% Notes ($1.05 billion) and 3.750% Notes ($1.7 billion).
- Review the company's most recent 10-Q or 10-K to assess the impact of this debt reduction on overall leverage ratios and liquidity.
- Check for any associated one-time charges or gains/losses on extinguishment of debt in the upcoming earnings report.